Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000076441 | SCV000107465 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Coding sequence variation introducing premature termination codon |
| Ambry Genetics | RCV002426635 | SCV002727862 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-02-15 | criteria provided, single submitter | clinical testing | The c.223_224delCT pathogenic mutation, located in coding exon 2 of the MSH2 gene, results from a deletion of two nucleotides at nucleotide positions 223 to 224, causing a translational frameshift with a predicted alternate stop codon (p.L75Afs*6). This mutation was first reported in a patient who fulfilled clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC) defined at the 34th Annual Meeting of Japanese Society for Cancer of the Colon and Rectum in Tokushima, Japan, 1991. RT-PCR followed by direct sequencing confirmed the presence of a premature stop codon in MSH2 mutant transcripts, which were susceptible to nonsense-mediated decay (Nomura S et al. Biochem Biophys Res Commun, 2000 Apr;271:120-9). This variant has been identified in at least one patient with a personal and family history of breast and/or ovarian cancer (Maxwell KN et al. Am J Hum Genet, 2016 May;98:801-817). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |